Cyclosporine藥物市場報告：2031 年趨勢、預測與競爭分析

全球Cyclosporine藥物市場前景光明，在移植排斥預防、類風濕性關節炎、乾癬、乾眼症和自體免疫重症肌無力市場都存在機會。預計2025年至2031年期間，全球Cyclosporine藥物市場的複合年成長率將達到17.3%。這個市場的主要促進因素包括類風濕性關節炎和乾癬等自體免疫疾病的盛行率不斷上升、全球器官移植數量的不斷增加以及藥物輸送系統的不斷進步。

• Lucintel 預測口服藥物在預測期內將出現高速成長。
• 根據應用情況，預防移植排斥預計將實現最高成長。
• 根據地區來看，預計亞太地區將在預測期內實現最高成長。

Cyclosporine藥物市場的新趨勢

由於專利到期、非專利競爭以及藥物輸送技術的進步，免疫抑制必需Cyclosporine藥物市場正在快速發展。改善患者療效、控制副作用、確保成本效益是塑造市場的關鍵促進因素。這些因素催生了若干關鍵趨勢，這些趨勢將影響Cyclosporine的配製、給藥方式以及患者取得方式。這些趨勢不僅影響市場動態，也有助於改善患者的治療和療效。

• 非專利的興起：原研究Cyclosporine藥物專利到期為學名藥的進入鋪平了道路。競爭加劇壓低了藥品價格，使更多患者負擔得起Cyclosporine治療。學名藥的興起對市場佔有率和定價產生了重大影響。
• 專注於改進藥物傳輸系統：目前正在開發新的藥物傳輸系統，以提高Cyclosporine的生物有效性並減少其副作用。這些進展旨在提高患者的依從性、療效和整體治療效果。輸送系統的改進對於最佳化Cyclosporine治療至關重要。
• 個人化醫療和治療藥物監測 (TDM)：Cyclosporine的治療窗較窄，需要仔細的劑量監測。 TDM 的日益普及使得個別化給藥成為可能，從而最佳化療效並最大程度降低毒性。這一趨勢正在改善患者的安全性和療效。
• 注重成本效益：醫療保健系統越來越注重成本控制，這推動了對具成本效益Cyclosporine劑型和治療策略的需求。成本效益是影響市場進入和報銷決策的主要因素。
• 新型類似物和生物類似物的開發：研發重點是開發具有更優藥物動力學特性和更低副作用的新型Cyclosporine類似物和生物類似物。這些進展可望進一步改善患者預後並拓展治療選擇。

總的來說，這些趨勢正在重塑Cyclosporine藥物市場，提高藥物可負擔性、改善藥物傳遞、個人化治療、注重成本效益，進而改善患者的用藥管道、改善治療效果、增加市場競爭。

Cyclosporine藥物市場的最新趨勢

免疫抑制必需Cyclosporine藥物市場充滿活力，受專利到期、學名藥競爭以及藥物輸送技術進步的驅動。最佳化療效、控制副作用和確保成本效益是關鍵促進因素。近期趨勢反映了這些影響，重點是配方改進、生物相似藥和以患者為中心的治療方案。這些進步正在再形成市場，影響藥物的可及性、治療效果和競爭格局。

• Cyclosporine非專利藥供應增加：專利到期導致Cyclosporine學名藥製劑激增。這顯著增強了市場競爭，降低了價格，並改善了患者獲得這種必需藥物的管道。學名藥的供應提供了更多的治療選擇，尤其是在成本敏感的市場。
• 新型製劑的開發：製藥公司正在投資開發具有改進藥物動力學特徵的新型Cyclosporine劑型。這些製劑旨在提高生物有效性、減少副作用並改善患者依從性。這些進展提高了Cyclosporine的治療指數，從而改善了患者的生活品質。
• Cyclosporine生物相似藥的出現：Cyclosporine生物相似藥已進入市場，為原廠生物製藥提供了經濟高效的替代品。生物相似藥經過嚴格測試，證明與原廠產品一樣安全有效，在擴大治療選擇的同時，降低了醫療成本。
• 著重個人化醫療：治療藥物監測 (TDM) 在Cyclosporine治療中發揮日益重要的作用。基於 TDM 的個人化給藥可以最佳化藥物濃度，最大限度地提高療效，並最大限度地降低毒性。這種以患者為中心的方法改善了治療效果，並減少了不利事件。
• 重視病患援助項目：製藥公司和醫療保健機構正在實施病患援助項目，以提高病患對Cyclosporine治療的依從性。這些計畫提供教育、諮詢和經濟援助，以解決治療障礙並改善長期療效。此類項目能夠加強與患者的關係，並提高治療成功率。

這些新興市場的發展對Cyclosporine藥物市場產生了集體影響，包括提高可負擔性、改善藥物輸送和療效、增加個人化醫療和加強患者倡導，這將改善患者的可及性、改善治療結果和增加市場競爭，最終使需要長期免疫抑制的患者受益。

目錄

第1章執行摘要

第2章全球Cyclosporine藥物市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球Cyclosporine藥物市場趨勢（2019-2024）及預測（2025-2031）
• 全球Cyclosporine藥物市場類型
  • 口服
  • 腸外
• 全球Cyclosporine藥物市場（按應用）
  • 預防移植排斥
  • 類風濕性關節炎
  • 乾癬
  • 眼睛乾澀
  • 自體免疫重症肌無力
  • 其他

第4章區域市場趨勢與預測分析（2019-2031）

• 全球Cyclosporine藥物市場（按地區）
• 北美Cyclosporine藥物市場
• 歐洲Cyclosporine藥物市場
• 亞太地區Cyclosporine藥物市場
• 世界其他地區的Cyclosporine藥物市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球Cyclosporine藥物市場成長機會（按類型）
  • 全球Cyclosporine藥物市場的成長機會（按應用）
  • 全球Cyclosporine藥物市場各區域成長機會
• 全球Cyclosporine藥物市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球Cyclosporine藥物市場的產能擴張
  • 全球Cyclosporine藥物市場的企業合併
  • 認證和許可

第7章主要企業簡介

• AbbVie
• Allergan
• Apotex
• Mayne Pharma Group
• Mckesson Medical Surgical
• Novartis
• Otsuka Pharmaceutical
• Regenerx Biopharmaceuticals
• Santen Pharmaceuticals
• Sun Pharmaceuticals Industries

The future of the global cyclosporine drug market looks promising with opportunities in the transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, dry eye, and autoimmune myasthenia gravis markets. The global cyclosporine drug market is expected to grow with a CAGR of 17.3% from 2025 to 2031. The major drivers for this market are the increasing prevalence of autoimmune diseases such as rheumatoid arthritis & psoriasis, the rising number of organ transplant procedures globally, and the growing advancements in drug delivery systems.

• Lucintel forecasts that, within the type category, oral is expected to witness higher growth over the forecast period.
• Within the application category, transplant rejection prophylaxis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Cyclosporine Drug Market

The cyclosporine drug market, essential for immunosuppression, is evolving rapidly due to patent expirations, generic competition, and advancements in drug delivery. Improving patient outcomes, managing side effects, and ensuring cost-effectiveness are key drivers shaping the market. These factors are leading to the emergence of several significant trends, impacting how cyclosporine is formulated, administered, and accessed by patients. These trends are not only influencing market dynamics but also improving patient care and treatment outcomes.

• Rise of Generic Formulations: Patent expirations of branded cyclosporine drugs have paved the way for the entry of generic versions. This increased competition is driving down drug prices, making cyclosporine therapy more affordable and accessible to a wider patient population. The rise of generics is significantly impacting market share and affordability.
• Focus on Improved Drug Delivery Systems: Novel drug delivery systems are being developed to enhance bioavailability and reduce the side effects associated with cyclosporine. These advancements aim to improve patient compliance, therapeutic efficacy, and overall treatment outcomes. Improved delivery systems are crucial for optimizing cyclosporine therapy.
• Personalized Medicine and Therapeutic Drug Monitoring (TDM): Cyclosporine's narrow therapeutic window necessitates careful dose monitoring. The increasing use of TDM allows for personalized dosing, optimizing efficacy, and minimizing toxicity. This trend is improving patient safety and treatment outcomes.
• Emphasis on Cost-Effectiveness: Healthcare systems are increasingly focused on cost containment. This is driving the demand for cost-effective cyclosporine formulations and treatment strategies. Cost-effectiveness is a major factor influencing market access and reimbursement decisions.
• Development of Novel Analogs and Biosimilars: Research and development efforts are focused on creating novel cyclosporine analogs and biosimilars with improved pharmacokinetic profiles and reduced side effects. These advancements have the potential to further improve patient outcomes and expand treatment options.

These trends are collectively reshaping the cyclosporine drug market by increasing affordability, improving drug delivery, personalizing treatment, and focusing on cost-effectiveness. They are leading to better patient access, improved treatment outcomes, and a more competitive market landscape.

Recent Developments in the Cyclosporine Drug Market

The cyclosporine drug market, vital for immunosuppression, is dynamic, influenced by patent expirations, generic competition, and advancements in drug delivery. Optimizing efficacy, managing side effects, and ensuring cost-effectiveness are key drivers. Recent developments reflect these influences, with a focus on improved formulations, biosimilars, and patient-centric approaches. These advancements are reshaping the market, impacting accessibility, treatment outcomes, and the competitive landscape.

• Increased Availability of Generic Cyclosporine: Patent expirations have led to a surge in generic cyclosporine formulations. This has significantly increased market competition, driving down prices and improving patient access to this essential medication. The availability of generics has broadened treatment options, particularly in cost-sensitive markets.
• Development of Novel Formulations: Pharmaceutical companies are investing in developing novel cyclosporine formulations with improved pharmacokinetic profiles. These formulations aim to enhance bioavailability, reduce side effects, and improve patient compliance. These advancements are improving the therapeutic index of cyclosporine and enhancing patient quality of life.
• Emergence of Cyclosporine Biosimilars: Biosimilar versions of cyclosporine are entering the market, offering cost-effective alternatives to branded biologics. Biosimilars are rigorously tested to demonstrate comparable safety and efficacy to the reference product, expanding treatment options while managing healthcare costs.
• Focus on Personalized Medicine: Therapeutic drug monitoring (TDM) is playing an increasingly important role in cyclosporine therapy. Personalized dosing based on TDM allows for optimizing drug levels, maximizing efficacy, and minimizing toxicity. This patient-centric approach is improving treatment outcomes and reducing adverse events.
• Emphasis on Patient Support Programs: Pharmaceutical companies and healthcare providers are implementing patient support programs to improve adherence to cyclosporine therapy. These programs offer education, counseling, and financial assistance, addressing barriers to treatment and improving long-term outcomes. Such programs enhance patient engagement and optimize treatment success.

These developments are collectively impacting the cyclosporine drug market by increasing affordability, improving drug delivery and efficacy, promoting personalized medicine, and enhancing patient support. They are leading to better patient access, improved treatment outcomes, and a more competitive market landscape, ultimately benefiting patients requiring long-term immunosuppression.

Strategic Growth Opportunities in the Cyclosporine Drug Market

The cyclosporine drug market, crucial for immunosuppression, is evolving with growth opportunities driven by increasing transplant procedures, autoimmune disease prevalence, and advancements in drug delivery. While generic competition impacts pricing, the need for effective and personalized immunosuppression creates avenues for innovation and market expansion. These opportunities focus on optimizing cyclosporine therapy for specific patient populations and improving long-term outcomes. Capitalizing on these opportunities requires a strategic focus on research, development, and patient-centric approaches.

• Expanding Organ Transplantation: The increasing success rates of organ transplantation are driving the demand for cyclosporine as a cornerstone of immunosuppressive regimens. Growth opportunities exist in developing tailored cyclosporine therapies for specific organ transplants, improving graft survival rates, and minimizing long-term complications. This focus enhances transplant outcomes and expands the pool of eligible recipients.
• Autoimmune Disease Management: Cyclosporine's efficacy in managing various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, presents significant growth opportunities. Developing targeted cyclosporine formulations for specific autoimmune conditions can improve treatment outcomes and reduce the burden of these chronic illnesses.
• Pediatric and Geriatric Populations: Specialized cyclosporine formulations and dosing strategies for pediatric and geriatric patients represent a key growth area. These populations often require adjusted dosing and careful monitoring due to differences in metabolism and potential comorbidities. Tailored therapies can optimize safety and efficacy in these vulnerable groups.
• Novel Drug Delivery Systems: Advancements in drug delivery, such as nanoparticles and sustained-release formulations, offer opportunities to improve cyclosporine bioavailability, reduce side effects, and enhance patient compliance. These innovations can improve therapeutic outcomes and quality of life for patients requiring long-term immunosuppression.
• Combination Therapies: Exploring combination therapies involving cyclosporine and other immunosuppressants or immunomodulators presents growth opportunities for optimizing treatment protocols. Such approaches can potentially reduce cyclosporine dosage, minimize toxicity, and improve long-term outcomes in transplant recipients and patients with autoimmune diseases.

These growth opportunities are collectively impacting the cyclosporine drug market by driving innovation in drug delivery, expanding treatment options for various patient populations, and promoting personalized medicine approaches. They are contributing to improved patient outcomes, enhanced quality of life, and a more competitive market landscape, ultimately benefiting patients requiring effective and well-tolerated immunosuppression.

Cyclosporine Drug Market Driver and Challenges

The cyclosporine drug market, vital for immunosuppression, is shaped by a complex interplay of drivers and challenges. These factors encompass technological advancements in drug delivery, economic pressures from generic competition, evolving regulatory landscapes, and the increasing demand for personalized medicine. Understanding these influences is crucial for navigating this dynamic market and ensuring access to effective and affordable cyclosporine therapy. These drivers and challenges are influencing research and development, pricing strategies, and patient access to this essential medication.

The factors responsible for driving the cyclosporine drug market include:

1. Rising Prevalence of Organ Transplants: The increasing success and frequency of organ transplantation procedures drive the demand for effective immunosuppressant drugs like cyclosporine. As transplant rates rise, the need for long-term immunosuppression, including cyclosporine-based regimens, also increases, fueling market growth.

2. Growing Burden of Autoimmune Diseases: The rising prevalence of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, contributes to the demand for cyclosporine. Cyclosporine's efficacy in managing these conditions makes it a valuable therapeutic option, driving market expansion.

3. Advancements in Drug Delivery: Innovations in drug delivery systems, such as nanoparticles and modified-release formulations, are improving cyclosporine's bioavailability and reducing side effects. These advancements enhance patient compliance and therapeutic outcomes, driving market growth for advanced formulations.

4. Focus on Personalized Medicine: The increasing emphasis on personalized medicine and therapeutic drug monitoring (TDM) is influencing the cyclosporine market. TDM allows for individualized dosing, optimizing efficacy and minimizing toxicity, leading to better patient management and potentially increased drug utilization.

5. Expanding Healthcare Access: Improved healthcare access in many regions is increasing the availability of organ transplantation and treatment for autoimmune diseases. This expansion in access contributes to the demand for cyclosporine, particularly in emerging markets.

Challenges in the cyclosporine drug market are:

1. Generic Competition and Price Erosion: Patent expirations have led to the entry of numerous generic cyclosporine formulations, significantly increasing market competition and driving down prices. This price erosion, while beneficial for patients, can impact profitability for pharmaceutical companies.

2. Safety and Toxicity Concerns: Cyclosporine's narrow therapeutic window and potential for serious side effects, such as nephrotoxicity and hypertension, pose a significant challenge. Managing these risks requires careful monitoring and dose adjustments, adding complexity to treatment.

3. Regulatory Scrutiny: Stringent regulatory requirements for new cyclosporine formulations and biosimilars can be a challenge. Meeting these requirements, including demonstrating bioequivalence and safety, can be costly and time-consuming, impacting market entry for new products.

These drivers and challenges collectively shape the cyclosporine drug market. While the drivers create opportunities for growth and innovation, the challenges related to generic competition, safety concerns, and regulatory hurdles must be addressed strategically. The market's future will depend on balancing affordability, efficacy, and safety to ensure optimal patient care and access to this critical medication.

List of Cyclosporine Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cyclosporine drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cyclosporine drug companies profiled in this report include-

• AbbVie
• Allergan
• Apotex
• Mayne Pharma Group
• McKesson Medical Surgical
• Novartis
• Otsuka Pharmaceutical
• Regenerx Biopharmaceuticals
• Santen Pharmaceuticals
• Sun Pharmaceuticals Industries

Cyclosporine Drug Market by Segment

The study includes a forecast for the global cyclosporine drug market by type, application, and region.

Cyclosporine Drug Market by Type [Value from 2019 to 2031]:

• Oral
• Parenteral

Cyclosporine Drug Market by Application [Value from 2019 to 2031]:

• Transplant Rejection Prophylaxis
• Rheumatoid Arthritis
• Psoriasis
• Dry Eye
• Autoimmune Myasthenia Gravis
• Others

Cyclosporine Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cyclosporine Drug Market

The cyclosporine drug market, crucial for immunosuppression in organ transplantation and autoimmune diseases, is experiencing a dynamic period marked by patent expirations, the rise of generics, and evolving formulations. Cyclosporine's narrow therapeutic window necessitates careful monitoring and personalized dosing, making advancements in drug delivery and therapeutic drug monitoring (TDM) significant. Furthermore, cost-effectiveness and accessibility are key factors influencing market dynamics, particularly in emerging economies. These factors are driving innovation and competition within the cyclosporine market globally.

• United States: The US market is mature, with a strong presence of both branded and generic cyclosporine formulations. Focus is on bioequivalence studies for generics and the development of novel drug delivery systems to improve patient compliance and reduce side effects. The high cost of healthcare in the US continues to be a major factor influencing market access and reimbursement policies.
• China: The Chinese cyclosporine market is growing rapidly, driven by increasing organ transplantation procedures and rising healthcare expenditure. Domestic pharmaceutical companies are focusing on developing generic versions of cyclosporine, which is increasing market competition. Accessibility and affordability are key concerns in this market.
• Germany: Germany has a well-established cyclosporine market, with a strong emphasis on quality and efficacy. The market is characterized by a high adoption of advanced formulations and a focus on personalized medicine. Germany's robust healthcare system ensures patient access to cyclosporine therapy.
• India: The Indian cyclosporine market is expanding, driven by a large population and growing awareness of autoimmune diseases. Generic manufacturers play a significant role, making cyclosporine more affordable and accessible. The focus is on developing cost-effective formulations and improving drug delivery systems.
• Japan: Japan has a mature cyclosporine market, with a focus on high-quality generics and innovative formulations. The market is characterized by a strong regulatory framework and a focus on patient safety. Japan's aging population contributes to the demand for cyclosporine for age-related autoimmune conditions.

Features of the Global Cyclosporine Drug Market

Market Size Estimates: Cyclosporine drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Cyclosporine drug market size by type, application, and region in terms of value ($B).

Regional Analysis: Cyclosporine drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the cyclosporine drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cyclosporine drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cyclosporine drug market by type (oral and parenteral), application (transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, dry eye, autoimmune myasthenia gravis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cyclosporine Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Cyclosporine Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Cyclosporine Drug Market by Type
  • 3.3.1: Oral
  • 3.3.2: Parenteral
• 3.4: Global Cyclosporine Drug Market by Application
  • 3.4.1: Transplant Rejection Prophylaxis
  • 3.4.2: Rheumatoid Arthritis
  • 3.4.3: Psoriasis
  • 3.4.4: Dry Eye
  • 3.4.5: Autoimmune Myasthenia Gravis
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Cyclosporine Drug Market by Region
• 4.2: North American Cyclosporine Drug Market
  • 4.2.1: North American Market by Type: Oral and Parenteral
  • 4.2.2: North American Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.3: European Cyclosporine Drug Market
  • 4.3.1: European Market by Type: Oral and Parenteral
  • 4.3.2: European Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.4: APAC Cyclosporine Drug Market
  • 4.4.1: APAC Market by Type: Oral and Parenteral
  • 4.4.2: APAC Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.5: ROW Cyclosporine Drug Market
  • 4.5.1: ROW Market by Type: Oral and Parenteral
  • 4.5.2: ROW Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cyclosporine Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Cyclosporine Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Cyclosporine Drug Market by Region
• 6.2: Emerging Trends in the Global Cyclosporine Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cyclosporine Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cyclosporine Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AbbVie
• 7.2: Allergan
• 7.3: Apotex
• 7.4: Mayne Pharma Group
• 7.5: Mckesson Medical Surgical
• 7.6: Novartis
• 7.7: Otsuka Pharmaceutical
• 7.8: Regenerx Biopharmaceuticals
• 7.9: Santen Pharmaceuticals
• 7.10: Sun Pharmaceuticals Industries